Menu

Prominent Salk Institute Scientist Inder Verma Resigns

His decision came as an investigation into sexual harassment allegations against him was ongoing.  

Jun 12, 2018
Sukanya Charuchandra

The Salk Institute of Biological StudiesISTOCK, DOUGBERRYInder Verma, a leading cancer researcher at the Salk Institute for Biological Studies, resigned on June 6 during an investigation into sexual harassment allegations against him, reports Science. In a letter on June 11, Dan Lewis, the chair of the Board of Trustees and Rusty Gage, the president of the Institute, say the Board unanimously accepted Verma’s “unconditional resignation,” calling it an “appropriate responsive action,” without offering any specifics of the investigation.

According to Science, Salk hired The Rose Group, a law firm, to investigate the case against Verma in March. Following Science’s April reporting of sexual misconduct allegations by eight women with connections to the institute, Verma was placed on administrative leave. This was in addition to his suspension as PNAS’s editor-in-chief after a gender discrimination lawsuit was filed against the Salk Institute.

Verma claims he has never misbehaved, reports The San Diego Union-Tribune. In an email to the newspaper in April, he said, “I have never used my position at the Salk Institute to take advantage of others.” He went on to add, “I have also never engaged in any sort of intimate relationship with anyone affiliated with the Salk Institute.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!